Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for OptimizeRx (OPRX) over the last 16 years, with Q2 2025 value amounting to $34000.0.

  • OptimizeRx's Capital Expenditures fell 1500.0% to $34000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $194000.0, marking a year-over-year increase of 13579.34%. This contributed to the annual value of $338000.0 for FY2024, which is 5688.78% down from last year.
  • As of Q2 2025, OptimizeRx's Capital Expenditures stood at $34000.0, which was down 1500.0% from $57000.0 recorded in Q1 2025.
  • Over the past 5 years, OptimizeRx's Capital Expenditures peaked at $1.5 million during Q3 2023, and registered a low of -$777000.0 during Q4 2023.
  • Its 5-year average for Capital Expenditures is $96707.0, with a median of $31500.0 in 2023.
  • Over the last 5 years, OptimizeRx's Capital Expenditures had its largest YoY gain of 638037.03% in 2023, and its largest YoY loss of 88569.77% in 2023.
  • Over the past 5 years, OptimizeRx's Capital Expenditures (Quarter) stood at $301601.0 in 2021, then plummeted by 67.21% to $98893.0 in 2022, then crashed by 885.7% to -$777000.0 in 2023, then soared by 113.26% to $103000.0 in 2024, then crashed by 66.99% to $34000.0 in 2025.
  • Its Capital Expenditures was $34000.0 in Q2 2025, compared to $57000.0 in Q1 2025 and $103000.0 in Q4 2024.